The DOI matches its Crossref record.
Experimental autoimmune encephalomyelitis is exacerbated by IL-1 alpha and suppressed by soluble IL-1 receptor
Abstract
To assess the role of IL-1 in the development of experimental autoimmune encephalomyelitis (EAE), the effects of in vivo treatment with IL-1 alpha or an IL-1 antagonist on the clinical course of EAE were evaluated. First, Lewis rats were immunized with guinea pig myelin in CFA and treated for 19 consecutive days with i.p. injections of recombinant human IL-1 alpha. Clinical signs of paralysis in the IL-1 alpha-treated groups were of longer duration and of greater severity compared to placebo injected controls. In addition, more weight loss was observed in the IL-1 alpha-treated groups compared to controls. This enhanced weight loss was not due to IL-1 alpha injections alone as CFA-treated rats injected with IL-1 alpha did not lose weight when compared to placebo injected, CFA-treated controls. Second, soluble mouse rIL-1R (sIL-1R), which binds both IL-1 alpha and IL-1 beta, was given as an IL-1 antagonist. Treatment of guinea pig myelin/CFA immunized rats with sIL-1R for 13 consecutive days significantly delayed the onset of EAE, reduced the severity of paralysis and weight loss, and shortened the duration of disease. Treatment with sIL-1R was most effective in reducing EAE if administered for 15 consecutive days immediately after immunization. Shortened 5-day treatment regimens spanning days 1 to 5, days 6 to 10, or days 11 to 15 after immunization were less effective in reducing EAE. These data suggest that IL-1 may initiate or promote inflammation within the central nervous system. In addition, specifically blocking the biological activity of IL-1 in vivo by soluble receptors may prove beneficial for the treatment of autoimmune or inflammatory diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
The Role of Interleukin-1 in Disease
Epstein, F. H., Dinarello, C. A., & Wolff, S. M. (1993) · New England Journal of Medicine · doi:10.1056/nejm199301143280207 · Cited by 954
IL-18: A TH1 -inducing, proinflammatory cytokine and new member of the IL-1 family
Dinarello, C. A. (1999) · Journal of Allergy and Clinical Immunology · doi:10.1016/s0091-6749(99)70518-x · Cited by 819
Shi, H., Wang, Y., Li, X., Zhan, X., Tang, M., Fina, M., Su, L., Pratt, D., Bu, C. H., Hildebrand, S., et al. (2016) · Nature Immunology · doi:10.1038/ni.3333 · Cited by 745
Cytokines in Inflammatory Bowel Disease
Rogler, G., & Andus, T. (1998) · World Journal of Surgery · doi:10.1007/s002689900401 · Cited by 484
Immunological aspects of experimental allergic encephalomyelitis and multiple sclerosis
Martin, R., McFarland, H. F., & Boggs, J. M. (1995) · Critical Reviews in Clinical Laboratory Sciences · doi:10.3109/10408369509084683 · Cited by 376
Metadata
- Authors
- Jacobs, C. A., Baker, P. E., Roux, E. R., Picha, K. S., Toivola, B., Waugh, S., & Kennedy, M. K.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 1991-05-01
- Volume
- 146
- Issue
- 9
- Pages
- 2983-2989
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W1932588934
- Cited by
- 181
- References
- 0
- FWCI
- 12.83
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Experimental autoimmune encephalomyelitis is exacerbated by IL-1 alpha and suppressed by soluble IL-1 receptor. https://app.cochat.ai/papers/10.4049/jimmunol.146.9.2983
- The paper
- Jacobs, C. A., Baker, P. E., Roux, E. R., Picha, K. S., Toivola, B., Waugh, S., & Kennedy, M. K. (1991). Experimental autoimmune encephalomyelitis is exacerbated by IL-1 alpha and suppressed by soluble IL-1 receptor. The Journal of Immunology. https://doi.org/10.4049/jimmunol.146.9.2983
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.